Bioiberica has won the 2025 European New Product Innovation Award from Frost & Sullivan for its clinically validated Native Type II Collagen ingredient, Collavant® n2. This recognition highlights the company’s leadership in scientific validation and ingredient differentiation. It also reinforces Bioiberica’s strong position in the European joint health market.
Native Type II Collagen Recognized for Innovation
Frost & Sullivan evaluates companies based on strategy and execution. Bioiberica performed strongly in both areas. The company aligned its long-term scientific research with growing market demand. At the same time, it maintained strict regulatory standards.
Moreover, Collavant® n2 stands out in a crowded collagen market. Many collagen products lack strong clinical backing. However, Native Type II Collagen from Bioiberica offers mechanistic clarity and proven efficacy. Clinical studies show support for joint comfort and mobility. In addition, research suggests potential cartilage preservation benefits.
Clinically Validated Collavant® n2
Collavant® n2 is derived from chicken sternum cartilage. Unlike denatured collagen peptides, it preserves its natural molecular structure. As a result, it works effectively at a low daily dose of 40 mg.
Furthermore, its immune-mediated mechanism of action is supported by randomized, controlled clinical trials. These studies demonstrate improvements in joint comfort, functional performance, and mobility. Therefore, Native Type II Collagen provides a science-based solution for both clinical and lifestyle nutrition segments.
Bioiberica continues to invest in research and pharmaceutical-grade production. Consequently, the company ensures full traceability and regulatory alignment. This strategy strengthens its credibility across European markets.
Strong Manufacturing and Customer Support
In addition to scientific innovation, Bioiberica supports manufacturers with formulation guidance and regulatory documentation. The company also offers clinically substantiated marketing support. As a result, partners can reduce formulation risk and accelerate product launches.
Through its vertically integrated supply chain within the SARIA Group, Bioiberica controls sourcing, processing, and production in Europe. This structure enhances quality and transparency. Independent NutraStrong™ Collagen Verification further strengthens consistency and customer trust.
Shaping the Future of Collagen Solutions
Each year, Frost & Sullivan presents the New Product Innovation Award to companies that demonstrate measurable differentiation and customer value. Bioiberica earned this recognition by combining clinical science with operational excellence.
Ultimately, this award confirms Bioiberica’s commitment to advancing Native Type II Collagen research. It also highlights the company’s role in driving evidence-based innovation in the European collagen industry.
Read Also: ImmunityBio Advances Regulatory Plans with SFDA Under Saudi-USA Biotech Alliance
